Paul Industries delivers CIP/SIP systems for pharmaceutical manufacturers as a single-source supplier and installer. We design, fabricate, install, passivate, and validate CIP/SIP systems – the clean-in-place and steam-in-place circuits that sterilize and clean a process train without disassembly – built to the standards your process and your auditors require.
What pharmaceutical manufacturers need from cip/sip systems
Pharmaceutical manufacturing lives and dies by cGMP compliance – FDA 21 CFR Parts 210/211, validated systems, and audit-ready documentation. Whether the process is oral solid dose, sterile injectables, or API synthesis, the utilities behind it (process water, clean steam, sanitary piping, CIP/SIP) have to be designed, installed, and documented to survive an FDA inspection.
For this work, that means cGMP (21 CFR 210/211) compliance, validated IQ/OQ/PQ turnover, USP-monograph water quality, and fully documented, traceable installations – not as an afterthought, but engineered in from the first drawing.
What we deliver
- Clean-in-place (CIP) skids – single-use or recirculating, with spray-device coverage engineered for full wetted-surface contact
- Steam-in-place (SIP) circuits designed for condensate removal, sterilization hold, and validated F0 delivery
- Integration with your process piping so CIP/SIP loops actually reach every dead-leg and instrument
- Cycle development and documentation to support cleaning and sterilization validation
- Controls and recipe management for repeatable, auditable cycles
One accountable partner
Most pharmaceutical projects get split between an equipment supplier and an install contractor – and the validation burden falls in the gap between them. Paul Industries closes that gap by self-performing the whole scope, from supply through documented turnover.
Related: CIP/SIP Systems services · Pharmaceutical Manufacturers solutions · Request a quote
Frequently asked questions
Why do pharmaceutical plants require CIP/SIP systems?
Because 21 CFR 211 requires equipment to be cleaned and maintained so it does not alter the safety, identity, strength, quality or purity of the product, and on closed process equipment that cannot be achieved reliably by hand. Clean-in-place makes the process reproducible and, critically, measurable: flow, temperature, concentration and contact time are recorded every cycle. Steam-in-place then provides sterility where the product requires it, with lethality demonstrated rather than assumed.
How does CIP/SIP apply to sterile fill-finish?
Sterile fill-finish equipment, holding tanks, and product lines must be both cleaned and sterilized before aseptic filling. CIP removes residues; SIP sterilizes the fluid path to a validated hold. Paul Industries designs the coverage and steam routing that fill-finish sterility assurance depends on.
Is CIP used for oral solid dose manufacturing?
Oral solid dose lines still need validated cleaning of granulation, coating, and liquid-prep equipment to prevent cross-contamination between products. CIP automates that on tanks and closed equipment, while dedicated wash approaches handle other units. Paul Industries scopes cleaning to each dosage-form’s equipment.
How is cleaning validation handled for pharmaceutical CIP?
Cleaning validation sets residue acceptance limits (often via MACO calculations for the active ingredient), then proves the CIP cycle meets them with swab and rinse sampling plus riboflavin coverage testing. Paul Industries builds systems and protocols that produce inspection-ready cleaning-validation evidence.
What is MACO and how does it affect CIP design?
MACO (Maximum Allowable Carryover) is the residue limit of one product permitted into the next, based on toxicity and batch size. Tighter MACO limits demand better coverage, hotter cycles, and thorough rinsing. CIP cycles are engineered to reliably meet the calculated limit.
How does CIP/SIP prevent cross-contamination in multi-product pharma facilities?
Shared equipment running different drugs must be cleaned to validated carryover limits between products. CIP delivers documented cleaning per changeover and SIP re-sterilizes, so no active ingredient or microbe carries into the next batch. Paul Industries designs for validated product-to-product changeover.
What FDA expectations apply to pharmaceutical CIP/SIP?
That cleaning is validated rather than merely performed, and that the evidence is specific to your product and your equipment. In practice inspectors look for calculated residue acceptance limits with a documented rationale, analytical methods validated for those residues, recovery studies performed on coupons of your actual contact surfaces rather than generic ones, sampling at worst-case locations with a justification for why those locations are worst case, and a documented approach to equipment grouping if you bracket products or equipment.
How are API and drug-substance systems cleaned?
API equipment can carry potent or hard-to-remove compounds requiring aggressive, validated cleaning chemistry and low residue limits. CIP circulates heated caustic and acid with proven coverage, followed by rinse sampling to confirm limits. Paul Industries develops chemistry matched to the specific API soil.
What water quality feeds pharmaceutical CIP rinses?
Final rinses typically use USP Purified Water or WFI so cleaning does not leave ionic or microbial residue on product-contact surfaces. Clean steam for SIP is generated from purified feedwater. Paul Industries integrates CIP/SIP with the compliant water and steam systems supplying them.
How is SIP validated for pharmaceutical equipment?
By mapping accumulated lethality rather than trusting a set point. Thermocouples go throughout the vessel and its associated pipework, deliberately at the locations expected to be coldest: low points, dead legs, valve bodies and the far ends of transfer lines. An F0 value is calculated at every probe and the cycle passes on the worst location reaching the required value, not the average. Biological indicators at those same positions give independent confirmation. Several development runs are normal.
What standards govern pharmaceutical CIP/SIP construction?
ASME BPE for the pipework, surface finish, drainability, joining and documentation, with ASME B31.3 governing pressure design. EN 285 supplies the physical steam quality criteria used when qualifying SIP, and clean steam condensate is held to the Water for Injection requirements. Passivation follows ASTM A967. The cleaning outcome itself is driven by 21 CFR 211, with EU GMP Annex 1 additionally applying to sterile manufacture supplied into Europe.
Can CIP/SIP be added to an existing pharmaceutical line?
Usually yes, and the constraint is utility capacity rather than physical space. A CIP system imposes a peak water and steam demand frequently larger than anything else in the plant, and loops sized before CIP was contemplated often cannot meet it alongside normal process draw. Tying into already-qualified equipment is also a change requiring assessment, with passivation of the new welds because the heat-affected zone is chromium-depleted, and fresh sampling before the line returns to service.
What causes pharmaceutical cleaning validation to fail?
Rarely the cleaning itself. The recurring failures are analytical: a method not validated for the specific residue, or recovery studies done on generic coupons rather than your actual surface finish, which produces a recovery factor that does not hold. Then sampling: locations chosen for accessibility rather than because they are worst case, with no documented rationale. Then limits: an acceptance limit carried over from another product without recalculating for batch size and shared surface area.
How does CIP/SIP support potent-compound (HPAPI) handling?
Highly potent APIs demand very low carryover limits and often containment-integrated cleaning. CIP cycles use validated chemistry and thorough rinsing to hit stringent MACO values, with coverage proven by testing. Paul Industries engineers cleaning around the potency and containment requirements.
How long does pharmaceutical CIP/SIP validation take?
Longer than the construction, and it is the part most often compressed in a schedule. Cycle development runs 12,000 to 45,000 dollars per circuit and each circuit needs its own development runs. SIP lethality mapping is 18,000 to 78,000 dollars per vessel and the first map commonly finds a cold spot requiring a mechanical change and a repeat. Cleaning validation then runs on analytical timelines. A multi-circuit system realistically takes nine to eighteen months from order to validated operation.
How do I start a pharmaceutical CIP/SIP project?
Send the equipment list with what each item holds, the number of distinct products sharing the train, the soils and whether they are water soluble, your available water, steam and effluent capacity, and whether SIP is required and on how many vessels. The product count matters as much as the circuit count, because each product entering a shared train triggers cleaning validation. If dedicating trains would cost less over the portfolio than validating changeovers, we will say so.
What pharmaceutical requirements do you build to?
ASME BPE for bioprocessing pipework including SF4 electropolished product contact surfaces where the fluid requires it, ASME B31.3 for pressure design, ASME Section IX for welder and procedure qualification, ASTM A967 for passivation, EN 285 for clean steam quality, and the USP monographs where compendial water is involved. The governing quality framework is 21 CFR 211, with EU GMP Annex 1 for sterile product supplied into Europe.
Get a single-source quote
Paul Industries designs, fabricates, installs, passivates, and validates – one accountable partner instead of a vendor plus a contractor plus a validation firm. Tell us about your project and we will scope it.
What do pharmaceutical CIP and SIP systems have to achieve?
| Requirement | What it means |
|---|---|
| Cleaning objective | Removal of product residue to a validated acceptance limit, with carryover calculated |
| Sterilization objective | SIP of product-contact surfaces using clean steam meeting EN 285 |
| Coverage | Spray device coverage proven, not assumed — riboflavin or equivalent |
| Velocity | Maintained at the FURTHEST point of the circuit, not at the skid outlet |
| Drainability | Full gravity drainage; retained solution defeats both CIP and SIP |
| Chemistry | Single-use or recirculated, with concentration verified in line |
| Records | Cycle data with audit trail under 21 CFR Part 11 |
| Validation | Cleaning validation with worst-case soil and hardest-to-clean location identified |
Do you handle validation, or just installation?
Both. In pharmaceutical manufacturing the cleaning validation carries more weight than the equipment, because a multi-product plant must demonstrate that residue from one product cannot reach an unacceptable level in the next, for every pairing in the matrix. Paul Industries performs the coverage testing, develops and documents the cycle recipes, executes the validation runs, and supports the carryover calculation derived from health-based exposure limits and shared surface area. We also set up the ongoing verification, meaning rinse conductivity, total organic carbon and periodic swabbing, that carries the validated state between formal revalidations. Installation without that evidence leaves the plant unable to defend its changeover.
Can you take a project from design through startup?
Yes. For a pharmaceutical plant the value of a single contract from design to startup is that the acceptance limit drives the design rather than being discovered afterwards. The worst-case product, its health-based exposure limit and the smallest subsequent batch size together set a residue limit per square centimeter, and that number determines spray device selection, circuit routing and cycle severity. Designing the skid first and calculating the limit later is how plants end up with a cleaning system that cannot reach its own acceptance criterion. We establish the limit at design stage and build backwards from it.